Results 131 to 140 of about 1,295,847 (252)

Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil   +5 more
wiley   +1 more source

Clinical Progression in Alpha‐Synuclein Positive LRRK2‐PD and Sporadic Parkinson's Disease: A Longitudinal Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse   +224 more
wiley   +1 more source

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross‐Sectional Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Female sex is an independent fall risk factor in Parkinson's disease (PD), yet sex‐specific fall patterns remain unclear. Objectives To compare sex‐specific fall risk and outcomes across PD, prodromal alpha‐synucleinopathy (PAS), and healthy controls (HC); estimate fall frequency across PD progression; and assess how sex modifies ...
Joaquin A. Vizcarra   +197 more
wiley   +1 more source

Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington's disease. [PDF]

open access: yesBrain
Ishtayeh H   +11 more
europepmc   +1 more source

Electroencephalography‐Based Clustering Reveals Robust Neurophysiological Subtypes in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with substantial variability in motor and cognitive features. Conventional clinical scales provide limited insight into underlying neural mechanisms and show poor longitudinal stability.
Daniel Vered   +4 more
wiley   +1 more source

GLP-1 Receptor Agonist Associated Unmasking of Insulinoma. [PDF]

open access: yesEur J Case Rep Intern Med
Simonov E   +4 more
europepmc   +1 more source

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

open access: yesMovement Disorders, EarlyView.
Abstract Background Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.
Leah V. Chifamba   +30 more
wiley   +1 more source

Home - About - Disclaimer - Privacy